1、Cronstein BN. Molecular therapeutics. Methotrexate and its
mechanism of action[ J]. Arthritis Rheum, 1996, 39(12): 1951-1960.Cronstein BN. Molecular therapeutics. Methotrexate and its
mechanism of action[ J]. Arthritis Rheum, 1996, 39(12): 1951-1960.
2、Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary
disease. Part 1: Cytotoxic drugs[ J]. Am Rev Respir Dis, 1986,133(2):
321-340.Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary
disease. Part 1: Cytotoxic drugs[ J]. Am Rev Respir Dis, 1986,133(2):
321-340.
3、Lynch JP 3rd, McCune WJ. Immunosuppressive and cytotoxic
pharmacotherapy for pulmonary disorders[ J]. Am J Respir Crit Care
Med, 1997, 155(2): 395-420.Lynch JP 3rd, McCune WJ. Immunosuppressive and cytotoxic
pharmacotherapy for pulmonary disorders[ J]. Am J Respir Crit Care
Med, 1997, 155(2): 395-420.
4、Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue
reactivity. II. Effect of aminopterin in rheumatoid arthritis and
psoriasis[ J]. Am J Med Sci, 1951, 221(2): 176-182.Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue
reactivity. II. Effect of aminopterin in rheumatoid arthritis and
psoriasis[ J]. Am J Med Sci, 1951, 221(2): 176-182.
5、Constantin T, Foeldvari I, Anton J, et al. Consensus-based
recommendations for the management of uveitis associated with
juvenile idiopathic arthritis: the SHARE initiative[ J]. Ann Rheum Dis,
2018, 77(8): 1107-1117.Constantin T, Foeldvari I, Anton J, et al. Consensus-based
recommendations for the management of uveitis associated with
juvenile idiopathic arthritis: the SHARE initiative[ J]. Ann Rheum Dis,
2018, 77(8): 1107-1117.
6、Sands DS, Chan SCY, Gottlieb CC. Methotrexate for the treatment of
noninfectious scleritis[ J]. Can J Ophthalmol, 2018, 53(4): 349-353.Sands DS, Chan SCY, Gottlieb CC. Methotrexate for the treatment of
noninfectious scleritis[ J]. Can J Ophthalmol, 2018, 53(4): 349-353.
7、Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college
of rheumatology/arthritis foundation guideline for the screening,
monitoring, and treatment of juvenile idiopathic arthritis-associated
uveitis[ J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716.Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college
of rheumatology/arthritis foundation guideline for the screening,
monitoring, and treatment of juvenile idiopathic arthritis-associated
uveitis[ J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716.
8、张晨星,周纬,孙广超，等.儿童免疫相关性疾病临床实用热点
问题专家建议系列之一：甲氨蝶呤在中国儿童风湿性疾病中
的应用建议[ J].中国实用儿科杂志, 2020, 35(3): 169-173.
Zhang CX, Zhou W, Sun GC, et al. Recommendations on clinical hot
topics related to immune related diseases in children: one of the expert
advice series on the application of methotrexate in rheumatic diseases
in children in China [ J]. Chin J Practi Pediatr, 2020, 35 (3): 169-173.张晨星,周纬,孙广超，等.儿童免疫相关性疾病临床实用热点
问题专家建议系列之一：甲氨蝶呤在中国儿童风湿性疾病中
的应用建议[ J].中国实用儿科杂志, 2020, 35(3): 169-173.
Zhang CX, Zhou W, Sun GC, et al. Recommendations on clinical hot
topics related to immune related diseases in children: one of the expert
advice series on the application of methotrexate in rheumatic diseases
in children in China [ J]. Chin J Practi Pediatr, 2020, 35 (3): 169-173.
9、Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for
ocular inflammatory diseases[ J]. Ophthalmology, 2009, 116(11):
2188-2198.e1.Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for
ocular inflammatory diseases[ J]. Ophthalmology, 2009, 116(11):
2188-2198.e1.
10、Durrani K , Zakka FR , Ahmed M, et al. Systemic therapy with
conventional and novel immunomodulatory agents for ocular inflammatory disease[ J]. Surv Ophthalmol, 2011, 56(6): 474-510.Durrani K , Zakka FR , Ahmed M, et al. Systemic therapy with
conventional and novel immunomodulatory agents for ocular inflammatory disease[ J]. Surv Ophthalmol, 2011, 56(6): 474-510.
11、Chang MH, Shantha JG, Fondriest JJ, et al. Uveitis in children and
adolescents[ J]. Rheum Dis Clin North Am, 2021, 47(4): 619-641.Chang MH, Shantha JG, Fondriest JJ, et al. Uveitis in children and
adolescents[ J]. Rheum Dis Clin North Am, 2021, 47(4): 619-641.
12、R athinam SR , Gonzales JA , Thundikandy R , et al. Effect of
corticosteroid-sparing treatment with mycophenolate mofetil vs
methotrexate on inflammation in patients with uveitis: a randomized
clinical trial[ J]. JAMA, 2019, 322(10): 936-945.R athinam SR , Gonzales JA , Thundikandy R , et al. Effect of
corticosteroid-sparing treatment with mycophenolate mofetil vs
methotrexate on inflammation in patients with uveitis: a randomized
clinical trial[ J]. JAMA, 2019, 322(10): 936-945.
13、Dugauquier A , Awada AH, Motulsky E, Kisma N. Intravitreal
methotrexate in vemurafenib-induced uveitis [ J]. Retin Cases Brief
Rep, 2023: 10.1097/ICB.0000000000001419.Dugauquier A , Awada AH, Motulsky E, Kisma N. Intravitreal
methotrexate in vemurafenib-induced uveitis [ J]. Retin Cases Brief
Rep, 2023: 10.1097/ICB.0000000000001419.
14、Chihara D, Dunleavy K. Primary central nervous system lymphoma:
evolving biologic insights and recent therapeutic advances[ J]. Clin
Lymphoma Myeloma Leuk, 2021, 21(2): 73-79.Chihara D, Dunleavy K. Primary central nervous system lymphoma:
evolving biologic insights and recent therapeutic advances[ J]. Clin
Lymphoma Myeloma Leuk, 2021, 21(2): 73-79.
15、Berenbom A, Rm D, Hs L, et al. Treatment outcomes for primary
intraocular lymphoma: implications for external beam radiotherapy[ J].
Eye, 2007, 21: 1198-1201.Berenbom A, Rm D, Hs L, et al. Treatment outcomes for primary
intraocular lymphoma: implications for external beam radiotherapy[ J].
Eye, 2007, 21: 1198-1201.
16、Abdi F, Mohammadi SS, Falavarjani KG. Intravitreal methotrexate[ J]. J
Ophthalmic Vis Res, 2021, 16(4): 657-669.Abdi F, Mohammadi SS, Falavarjani KG. Intravitreal methotrexate[ J]. J
Ophthalmic Vis Res, 2021, 16(4): 657-669.
17、Tang LJ, Gu CL, Zhang P. Intraocular lymphoma[ J]. Int J Ophthalmol,
2017, 10(8): 1301-1307.Tang LJ, Gu CL, Zhang P. Intraocular lymphoma[ J]. Int J Ophthalmol,
2017, 10(8): 1301-1307.
18、Simakurthy S, Jena S, Tripathy K. Primary Intraocular Lymphoma[M].
Treasure Island (FL): StatPearls Publishing, 2023.Simakurthy S, Jena S, Tripathy K. Primary Intraocular Lymphoma[M].
Treasure Island (FL): StatPearls Publishing, 2023.
19、Pastor%20JC%2C%20de%20la%20R%C3%BAa%20ER%2C%20Mart%C4%B1n%20F.%20Proliferative%20vitreoretinopathy%3A%20risk%20%0Afactors%20and%20pathobiology%5B%20J%5D.%20Prog%20Retin%20Eye%20Res%2C%202002%2C%2021(1)%3A%20127-%0A144.Pastor%20JC%2C%20de%20la%20R%C3%BAa%20ER%2C%20Mart%C4%B1n%20F.%20Proliferative%20vitreoretinopathy%3A%20risk%20%0Afactors%20and%20pathobiology%5B%20J%5D.%20Prog%20Retin%20Eye%20Res%2C%202002%2C%2021(1)%3A%20127-%0A144.
20、Sadaka A, Sisk RA, Osher JM, et al. Intravitreal methotrexate infusion
for proliferative vitreoretinopathy[ J]. Clin Ophthalmol, 2016, 10:
1811-1817.Sadaka A, Sisk RA, Osher JM, et al. Intravitreal methotrexate infusion
for proliferative vitreoretinopathy[ J]. Clin Ophthalmol, 2016, 10:
1811-1817.
21、McAllister MA, Moore SM, Bullock B, et al. Intraocular methotrexate
for the treatment and prevention of proliferative vitreoretinopathy: a
review[ J]. J Vitreoretin Dis, 2022, 7: 144-153.McAllister MA, Moore SM, Bullock B, et al. Intraocular methotrexate
for the treatment and prevention of proliferative vitreoretinopathy: a
review[ J]. J Vitreoretin Dis, 2022, 7: 144-153.
22、Benner JD, Dao D, Butler JW, et al. Intravitreal methotrexate for the
treatment of proliferative vitreoretinopathy[ J]. BMJ Open Ophthalmol,
2019, 4(1): e000293.Benner JD, Dao D, Butler JW, et al. Intravitreal methotrexate for the
treatment of proliferative vitreoretinopathy[ J]. BMJ Open Ophthalmol,
2019, 4(1): e000293.
23、Lambert NG, Wilson DJ, Albert DM, et al. Intravitreal methotrexate for
recurrent epithelial downgrowth[ J]. JAMA Ophthalmol, 2019, 137(9):
1082-1083.Lambert NG, Wilson DJ, Albert DM, et al. Intravitreal methotrexate for
recurrent epithelial downgrowth[ J]. JAMA Ophthalmol, 2019, 137(9):
1082-1083.
24、Joussen%20AM%2C%20Kruse%20FE%2C%20V%C3%B6lcker%20HE%2C%20et%20al.%20Topical%20application%20of%20%0Amethotrexate%20for%20inhibition%20of%20corneal%20angiogenesis%5B%20J%5D.%20Albrecht%20Von%20%0AGraefes%20Arch%20Fur%20Klinische%20Und%20Exp%20Ophthalmol%2C%201999%2C%20237(11)%3A%20920-%0A927.Joussen%20AM%2C%20Kruse%20FE%2C%20V%C3%B6lcker%20HE%2C%20et%20al.%20Topical%20application%20of%20%0Amethotrexate%20for%20inhibition%20of%20corneal%20angiogenesis%5B%20J%5D.%20Albrecht%20Von%20%0AGraefes%20Arch%20Fur%20Klinische%20Und%20Exp%20Ophthalmol%2C%201999%2C%20237(11)%3A%20920-%0A927.
25、Kurup SK , Gee C, Greven CM. Intrav itreal methotrexate in
therapeutically resistant exudative age-related macular degeneration[ J].
Acta Ophthalmol, 2010, 88(4): e145-e146.Kurup SK , Gee C, Greven CM. Intrav itreal methotrexate in
therapeutically resistant exudative age-related macular degeneration[ J].
Acta Ophthalmol, 2010, 88(4): e145-e146.
26、Bou R, Adán A, Borrás F, et al. Clinical management algorithm of
uveitis associated with juvenile idiopathic arthritis: interdisciplinary
panel consensus[ J]. Rheumatol Int, 2015, 35(5): 777-785.Bou R, Adán A, Borrás F, et al. Clinical management algorithm of
uveitis associated with juvenile idiopathic arthritis: interdisciplinary
panel consensus[ J]. Rheumatol Int, 2015, 35(5): 777-785.
27、Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile
idiopathic arthritis: advice and recommendations from the MARAJIA
expert consensus meeting[ J]. Pediatr Rheumatol Online J, 2018,
16(1): 46.Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile
idiopathic arthritis: advice and recommendations from the MARAJIA
expert consensus meeting[ J]. Pediatr Rheumatol Online J, 2018,
16(1): 46.
28、Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches
to autoimmune chronic uveitis in children[ J]. Autoimmun Rev, 2010,
9(10): 674-683.Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches
to autoimmune chronic uveitis in children[ J]. Autoimmun Rev, 2010,
9(10): 674-683.
29、Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral
methotrexate improves bioavailability: a pharmacokinetic study in
patients with rheumatoid arthritis[ J]. J Rheumatol, 2006, 33(3): 481-
485.Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral
methotrexate improves bioavailability: a pharmacokinetic study in
patients with rheumatoid arthritis[ J]. J Rheumatol, 2006, 33(3): 481-
485.
30、Dhaon P, Das SK, Srivastava R , et al. Oral Methotrexate in split
dose weekly versus oral or parenteral Methotrexate once weekly in
Rheumatoid Arthritis: a short-term study[ J]. Int J Rheum Dis, 2018,
21(5): 1010-1017.Dhaon P, Das SK, Srivastava R , et al. Oral Methotrexate in split
dose weekly versus oral or parenteral Methotrexate once weekly in
Rheumatoid Arthritis: a short-term study[ J]. Int J Rheum Dis, 2018,
21(5): 1010-1017.
31、Psoriasis-liver-methotrexate interactions[ J]. Arch Dermatol, 1973,
108(1): 36-42.Psoriasis-liver-methotrexate interactions[ J]. Arch Dermatol, 1973,
108(1): 36-42.
32、Smith JR , Rosenbaum JT, Wilson DJ, et al. Role of intravitreal
methotrexate in the management of primary central nervous system
lymphoma with ocular involvement[ J]. Ophthalmology, 2002, 109(9):
1709-1716.Smith JR , Rosenbaum JT, Wilson DJ, et al. Role of intravitreal
methotrexate in the management of primary central nervous system
lymphoma with ocular involvement[ J]. Ophthalmology, 2002, 109(9):
1709-1716.
33、de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for
the treatment of recurrent intraocular lymphoma[ J]. Br J Ophthalmol,
1999, 83(4): 448-451.de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for
the treatment of recurrent intraocular lymphoma[ J]. Br J Ophthalmol,
1999, 83(4): 448-451.
34、Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and
management[ J]. Cancer Control, 2004, 11(5): 285-295.Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and
management[ J]. Cancer Control, 2004, 11(5): 285-295.
35、Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a
diagnostic and management challenge[ J]. Blood, 2021, 138(17):1519-
1534.Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a
diagnostic and management challenge[ J]. Blood, 2021, 138(17):1519-
1534.
36、Anthony CL, Bavinger JC, Shantha JG, et al. Clinical outcomes
following intravitreal methotrexate for primar y vitreoretinal
lymphoma[ J]. Int J Retina Vitreous, 2021, 7(1): 72.Anthony CL, Bavinger JC, Shantha JG, et al. Clinical outcomes
following intravitreal methotrexate for primar y vitreoretinal
lymphoma[ J]. Int J Retina Vitreous, 2021, 7(1): 72.
37、Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab
for treatment of vitreoretinal lymphoma[ J]. Br J Ophthalmol, 2014,
98(1): 99-103.Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab
for treatment of vitreoretinal lymphoma[ J]. Br J Ophthalmol, 2014,
98(1): 99-103.
38、Zhou N, Xu X, Liu Y, et al. A proposed protocol of intravitreal injection
of methotrexate for treatment of primary vitreoretinal lymphoma[ J].
Eye, 2022, 36(7): 1448-1455.Zhou N, Xu X, Liu Y, et al. A proposed protocol of intravitreal injection
of methotrexate for treatment of primary vitreoretinal lymphoma[ J].
Eye, 2022, 36(7): 1448-1455.
39、Hasan N, Chawla R , Shaikh N, et al. A comprehensive review of intravitreal immunosuppressants and biologicals used inophthalmology [J].Ther Adv Ophthalmol,2022,14:25158414221097418.Hasan N, Chawla R , Shaikh N, et al. A comprehensive review of intravitreal immunosuppressants and biologicals used inophthalmology [J].Ther Adv Ophthalmol,2022,14:25158414221097418.
40、Taylor SR, Habot-Wilner Z, Pacheco P, et al. Intraocular methotrexate
in the treatment of uveitis and uveitic cystoid macular edema[ J].
Ophthalmology, 2009, 116(4): 797-801.Taylor SR, Habot-Wilner Z, Pacheco P, et al. Intraocular methotrexate
in the treatment of uveitis and uveitic cystoid macular edema[ J].
Ophthalmology, 2009, 116(4): 797-801.
41、Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can
induce extended remission in some patients in noninfectious uveitis[ J].
Retina, 2013, 33(10): 2149-2154.Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can
induce extended remission in some patients in noninfectious uveitis[ J].
Retina, 2013, 33(10): 2149-2154.
42、Khalil%20HEM%2C%20Raafat%20HA%2C%20Azab%20NA%2C%20et%20al.%20The%20role%20of%20intraocular%20%0Amethotrexate%20in%20the%20management%20of%20uveitis%20and%20posterior%20segment%20%0Ainvolvement%20in%20Beh%C3%A7et's%20disease%20patients%5B%20J%5D.%20Egypt%20Rheumatol%2C%202015%2C%20%0A37(3)%3A%20113-118.Khalil%20HEM%2C%20Raafat%20HA%2C%20Azab%20NA%2C%20et%20al.%20The%20role%20of%20intraocular%20%0Amethotrexate%20in%20the%20management%20of%20uveitis%20and%20posterior%20segment%20%0Ainvolvement%20in%20Beh%C3%A7et's%20disease%20patients%5B%20J%5D.%20Egypt%20Rheumatol%2C%202015%2C%20%0A37(3)%3A%20113-118.
43、Khalil%20HE%2C%20El%20Gendy%20HA%2C%20Youssef%20HA%2C%20et%20al.%20The%20effectiveness%20of%20%0Aintraocular%20methotrexate%20in%20the%20treatment%20of%20posterior%20uveitis%20in%20%0Abeh%C3%A7et's%20disease%20patients%20compared%20to%20retrobulbar%20steroids%20injection%5B%20J%5D.%20%0AJ%20Ophthalmol%2C%202016%2C%202016%3A%201678495.Khalil%20HE%2C%20El%20Gendy%20HA%2C%20Youssef%20HA%2C%20et%20al.%20The%20effectiveness%20of%20%0Aintraocular%20methotrexate%20in%20the%20treatment%20of%20posterior%20uveitis%20in%20%0Abeh%C3%A7et's%20disease%20patients%20compared%20to%20retrobulbar%20steroids%20injection%5B%20J%5D.%20%0AJ%20Ophthalmol%2C%202016%2C%202016%3A%201678495.
44、Park JG, Callaway NF, Ludwig CA, et al. Intravitreal methotrexate
and fluocinolone acetonide implantation for vogt-koyanagi-harada
uveitis[ J]. Am J Ophthalmol Case Rep, 2020, 19: 100859.Park JG, Callaway NF, Ludwig CA, et al. Intravitreal methotrexate
and fluocinolone acetonide implantation for vogt-koyanagi-harada
uveitis[ J]. Am J Ophthalmol Case Rep, 2020, 19: 100859.
45、Albrecht K, Müller-Ladner U. Side effects and management of side
effects of methotrexate in rheumatoid arthritis[ J]. Clin Exp Rheumatol,
2010, 28(5 Suppl 61): S95-101.Albrecht K, Müller-Ladner U. Side effects and management of side
effects of methotrexate in rheumatoid arthritis[ J]. Clin Exp Rheumatol,
2010, 28(5 Suppl 61): S95-101.
46、Smith JR , Rosenbaum JT, Wilson DJ, et al. Role of intravitreal
methotrexate in the management of primary central nervous system
lymphoma with ocular involvement[ J]. Ophthalmology, 2002, 109(9):
1709-1716.Smith JR , Rosenbaum JT, Wilson DJ, et al. Role of intravitreal
methotrexate in the management of primary central nervous system
lymphoma with ocular involvement[ J]. Ophthalmology, 2002, 109(9):
1709-1716.
47、Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary
intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[ J]. Ann
Hematol, 2016, 95(4): 593-601.Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary
intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[ J]. Ann
Hematol, 2016, 95(4): 593-601.
48、Huang YC, Jou JR. Intravitreal injections of methotrexate in treatment
of primary central nervous system lymphoma with intraocular
involvement[ J]. Kaohsiung J Med Sci, 2016, 32(12): 638-639.Huang YC, Jou JR. Intravitreal injections of methotrexate in treatment
of primary central nervous system lymphoma with intraocular
involvement[ J]. Kaohsiung J Med Sci, 2016, 32(12): 638-639.
49、Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk
factors for low dose methotrexate toxicity: a cohort of 28 patients[ J].
Autoimmun Rev, 2014, 13(11): 1109-1113.Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk
factors for low dose methotrexate toxicity: a cohort of 28 patients[ J].
Autoimmun Rev, 2014, 13(11): 1109-1113.
50、Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal
function in patients with rheumatoid arthritis receiving a standard dose
of oral weekly methotrexate: association with significant decreases in
creatinine clearance and renal clearance of the drug after 6 months of
therapy[ J]. J Rheumatol, 1995, 22(1): 38-40.Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal
function in patients with rheumatoid arthritis receiving a standard dose
of oral weekly methotrexate: association with significant decreases in
creatinine clearance and renal clearance of the drug after 6 months of
therapy[ J]. J Rheumatol, 1995, 22(1): 38-40.
51、Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory,
radiographic, and histopathologic features of methotrexate-associated
lung injury in patients with rheumatoid arthritis: a multicenter study
with literature review[ J]. Arthritis Rheum, 1997, 40(10):1829-1837.Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory,
radiographic, and histopathologic features of methotrexate-associated
lung injury in patients with rheumatoid arthritis: a multicenter study
with literature review[ J]. Arthritis Rheum, 1997, 40(10):1829-1837.
52、Ramírez Huaranga MA, Bencosme de Mendez E, Cuadra Díaz JL, et
al. Neumonitis por citomegalovirus durante el tratamiento crónico con
metotrexato[ J]. Reumatología Clínica, 2014, 10(5): 328-330.Ramírez Huaranga MA, Bencosme de Mendez E, Cuadra Díaz JL, et
al. Neumonitis por citomegalovirus durante el tratamiento crónico con
metotrexato[ J]. Reumatología Clínica, 2014, 10(5): 328-330.
53、Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties
of methotrexate: apoptosis and clonal deletion of activated peripheral T
cells[ J]. J Clin Invest, 1998, 102(2): 322-328.Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties
of methotrexate: apoptosis and clonal deletion of activated peripheral T
cells[ J]. J Clin Invest, 1998, 102(2): 322-328.
54、Vanni KMM, Lyu H, Solomon DH. Cytopenias among patients with
rheumatic diseases using methotrexate: a meta-analysis of randomized
controlled clinical trials[ J]. Rheumatology (Oxford), 2020, 59(4):
709-717.Vanni KMM, Lyu H, Solomon DH. Cytopenias among patients with
rheumatic diseases using methotrexate: a meta-analysis of randomized
controlled clinical trials[ J]. Rheumatology (Oxford), 2020, 59(4):
709-717.
55、Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a
predictor of hematologic toxicity due to methotrexate therapy[ J].
Arthritis Rheum, 1989, 32(12): 1592-1596.Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a
predictor of hematologic toxicity due to methotrexate therapy[ J].
Arthritis Rheum, 1989, 32(12): 1592-1596.
56、Saag KG, Teng GG, Patkar NM, et al. American College of
Rheumatology 2008 recommendations for the use of nonbiologic
and biologic disease-modifying antirheumatic drugs in rheumatoid
arthritis[ J]. Arthritis Rheum, 2008, 59(6): 762-784.Saag KG, Teng GG, Patkar NM, et al. American College of
Rheumatology 2008 recommendations for the use of nonbiologic
and biologic disease-modifying antirheumatic drugs in rheumatoid
arthritis[ J]. Arthritis Rheum, 2008, 59(6): 762-784.
57、中国医师协会风湿免疫科医师分会, 曾小峰. 甲氨蝶呤在风湿性疾病中的应用中国专家共识[J]. 中华内科杂志, 2018, 57(10): 719-722.
Rheumatology and Immunology Branch of the Chinese Medical
Doctor Association, Zeng XF. Chinese expert-based consensus for
methotrexate in rheumatic diseases[ J]. Chin J Intern Med, 2018,
57(10): 719-722.中国医师协会风湿免疫科医师分会, 曾小峰. 甲氨蝶呤在风湿性疾病中的应用中国专家共识[J]. 中华内科杂志, 2018, 57(10): 719-722.
Rheumatology and Immunology Branch of the Chinese Medical
Doctor Association, Zeng XF. Chinese expert-based consensus for
methotrexate in rheumatic diseases[ J]. Chin J Intern Med, 2018,
57(10): 719-722.
58、Micu MC, Ostensen M, Villiger PM, et al. Paternal exposure to
antirheumatic drugs-What physicians should know: review of the
literature[ J]. Semin Arthritis Rheum, 2018, 48(2): 343-355.Micu MC, Ostensen M, Villiger PM, et al. Paternal exposure to
antirheumatic drugs-What physicians should know: review of the
literature[ J]. Semin Arthritis Rheum, 2018, 48(2): 343-355.
59、Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men
trying to conceive: a systematic review and analysis of published
evidence[ J]. Semin Arthritis Rheum, 2019, 48(5): 911-920.Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men
trying to conceive: a systematic review and analysis of published
evidence[ J]. Semin Arthritis Rheum, 2019, 48(5): 911-920.
60、Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence
for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study[ J]. Rheumatology
(Oxford), 2014, 53(4): 757-763.Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence
for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study[ J]. Rheumatology
(Oxford), 2014, 53(4): 757-763.
61、Lee CY, Jin C, Mata AM, et al. A pilot study of paternal drug exposure:
the Motherisk experience[ J]. Reprod Toxicol, 2010, 29(3): 353-360.Lee CY, Jin C, Mata AM, et al. A pilot study of paternal drug exposure:
the Motherisk experience[ J]. Reprod Toxicol, 2010, 29(3): 353-360.
62、Beghin D, Cournot MP, Vauzelle C, et al. Paternal exposure to
methotrexate and pregnancy outcomes[ J]. J Rheumatol, 2011, 38(4):
628-632.Beghin D, Cournot MP, Vauzelle C, et al. Paternal exposure to
methotrexate and pregnancy outcomes[ J]. J Rheumatol, 2011, 38(4):
628-632.
63、Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150, 000
pregnant women and expectant fathers[ J]. Scand J Rheumatol, 2012,
41(3): 196-201.Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150, 000
pregnant women and expectant fathers[ J]. Scand J Rheumatol, 2012,
41(3): 196-201.
64、Wallenius M, Lie E, Daltveit AK, et al. No excess risks in offspring with
paternal preconception exposure to disease-modifying antirheumatic
drugs[ J]. Arthritis Rheumatol, 2015, 67(1): 296-301.Wallenius M, Lie E, Daltveit AK, et al. No excess risks in offspring with
paternal preconception exposure to disease-modifying antirheumatic
drugs[ J]. Arthritis Rheumatol, 2015, 67(1): 296-301.
65、Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on
prescribing drugs in pregnancy and breastfeeding-Part II: analgesics
and other drugs used in rheumatology practice[ J]. Rheumatology
(Oxford), 2016, 55(9): 1698-1702.Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on
prescribing drugs in pregnancy and breastfeeding-Part II: analgesics
and other drugs used in rheumatology practice[ J]. Rheumatology
(Oxford), 2016, 55(9): 1698-1702.
66、Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American
college of rheumatology guideline for the management of reproductive
health in rheumatic and musculoskeletal diseases[ J]. Arthritis
Rheumatol, 2020, 72(4): 529-556.Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American
college of rheumatology guideline for the management of reproductive
health in rheumatic and musculoskeletal diseases[ J]. Arthritis
Rheumatol, 2020, 72(4): 529-556.
67、Calvey N. Adverse drug reactions[ J]. AnaesthIntensive Care Medicine,
2008, 9(7): 319-323.Calvey N. Adverse drug reactions[ J]. AnaesthIntensive Care Medicine,
2008, 9(7): 319-323.
68、Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy[ J].
Lancet, 2012, 379(9815): 580-587.Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy[ J].
Lancet, 2012, 379(9815): 580-587.
69、Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital
anomalies associated with weekly low-dose methotrexate treatment of
the mother[ J]. Arthritis Rheum, 1997, 40(5): 971-973.Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital
anomalies associated with weekly low-dose methotrexate treatment of
the mother[ J]. Arthritis Rheum, 1997, 40(5): 971-973.
70、Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate-induced congenital
malformations[ J]. J Pediatr, 1968, 72(6): 790-795.Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate-induced congenital
malformations[ J]. J Pediatr, 1968, 72(6): 790-795.
71、Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy
outcome after methotrexate treatment for rheumatic disease prior to
or during early pregnancy: a prospective multicenter cohort study[ J].
Arthritis Rheumatol, 2014, 66(5):1101-1110.Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy
outcome after methotrexate treatment for rheumatic disease prior to
or during early pregnancy: a prospective multicenter cohort study[ J].
Arthritis Rheumatol, 2014, 66(5):1101-1110.
72、Verberne EA, Haan ED, van Tintelen JP, et al. Fetal methotrexate
syndrome: a systematic review of case reports[ J]. Reprod Toxicol,
2019, 87: 125-139.Verberne EA, Haan ED, van Tintelen JP, et al. Fetal methotrexate
syndrome: a systematic review of case reports[ J]. Reprod Toxicol,
2019, 87: 125-139.
73、Thorne JC, Nadarajah T, Moretti M, et al. Methotrexate use in a
breastfeeding patient with rheumatoid arthritis[ J]. J Rheumatol, 2014,
41(11): 2332.Thorne JC, Nadarajah T, Moretti M, et al. Methotrexate use in a
breastfeeding patient with rheumatoid arthritis[ J]. J Rheumatol, 2014,
41(11): 2332.
74、Johns DG, Rutherford LD, Leighton PC, et al. Secretion of
methotrexate into human milk[ J]. Am J Obstet Gynecol, 1972, 112(7):
978-980.Johns DG, Rutherford LD, Leighton PC, et al. Secretion of
methotrexate into human milk[ J]. Am J Obstet Gynecol, 1972, 112(7):
978-980.
75、Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on
prescribing drugs in pregnancy and breastfeeding-Part I: standard and
biologic disease modifying anti-rheumatic drugs and corticosteroids[ J].
Rheumatology (Oxford), 2016, 55(9): 1693-1697.Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on
prescribing drugs in pregnancy and breastfeeding-Part I: standard and
biologic disease modifying anti-rheumatic drugs and corticosteroids[ J].
Rheumatology (Oxford), 2016, 55(9): 1693-1697.
76、G%C3%B6testam%20Skorpen%20C%2C%20Hoeltzenbein%20M%2C%20Tincani%20A%2C%20et%20al.%20The%20EULAR%20%0Apoints%20to%20consider%20for%20use%20of%20antirheumatic%20drugs%20before%20pregnancy%2C%20and%20%0Aduring%20pregnancy%20and%20lactation%5B%20J%5D.%20Ann%20Rheum%20Dis%2C%202016%2C%2075(5)%3A%20795-%0A810.G%C3%B6testam%20Skorpen%20C%2C%20Hoeltzenbein%20M%2C%20Tincani%20A%2C%20et%20al.%20The%20EULAR%20%0Apoints%20to%20consider%20for%20use%20of%20antirheumatic%20drugs%20before%20pregnancy%2C%20and%20%0Aduring%20pregnancy%20and%20lactation%5B%20J%5D.%20Ann%20Rheum%20Dis%2C%202016%2C%2075(5)%3A%20795-%0A810.
77、Bechard MA, Lemieux JR, Roth J, et al. Procedural pain and patient-reported side effects with weekly injections of subcutaneous
methotrexate in children with rheumatic disorders[ J]. Pediatr
Rheumatol Online J, 2014, 12: 54.Bechard MA, Lemieux JR, Roth J, et al. Procedural pain and patient-reported side effects with weekly injections of subcutaneous
methotrexate in children with rheumatic disorders[ J]. Pediatr
Rheumatol Online J, 2014, 12: 54.
78、Al-Moujahed A, Saleh S, Ghoraba H, et al. Systemic and intraocular
methotrexate for the prevention and treatment of proliferative
vitreoretinopathy in children with rhegmatogenous retinal detachment
and underlying inflammatory disease[ J]. J Vitreoretin Dis, 2022, 6(5):
399-404.Al-Moujahed A, Saleh S, Ghoraba H, et al. Systemic and intraocular
methotrexate for the prevention and treatment of proliferative
vitreoretinopathy in children with rhegmatogenous retinal detachment
and underlying inflammatory disease[ J]. J Vitreoretin Dis, 2022, 6(5):
399-404.
79、Kremer J, Petrillo G, Hamilton R. Pharmacokinetics and renal function
in patients with rheumatoid arthritis receiving a standard dose of
oral weekly methotrexate: association with significant decreases in
creatinine clearance and renal clearance of the drug after 6 months of
therapy[ J]. Rheumatol, 1995, 22(1): 38-40.Kremer J, Petrillo G, Hamilton R. Pharmacokinetics and renal function
in patients with rheumatoid arthritis receiving a standard dose of
oral weekly methotrexate: association with significant decreases in
creatinine clearance and renal clearance of the drug after 6 months of
therapy[ J]. Rheumatol, 1995, 22(1): 38-40.
80、Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for
elevated transaminases in methotrexate users through an electronic
health record[ J]. Arthritis Care Res (Hoboken), 2014, 66(8): 1159-
1166.Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for
elevated transaminases in methotrexate users through an electronic
health record[ J]. Arthritis Care Res (Hoboken), 2014, 66(8): 1159-
1166.
81、Sipkova Z, Insull EA, David J, et al. Early use of steroid-sparing agents
in the inactivation of moderate-to-severe active thyroid eye disease: a
step-down approach[ J]. Clin Endocrinol (Oxf), 2018, 89(6): 834-839.Sipkova Z, Insull EA, David J, et al. Early use of steroid-sparing agents
in the inactivation of moderate-to-severe active thyroid eye disease: a
step-down approach[ J]. Clin Endocrinol (Oxf), 2018, 89(6): 834-839.
82、Malaviya AN, Sharma A, Agarwal D, et al. Low-dose and high-dose
methotrexate are two different drugs in practical terms[ J]. Int J Rheum
Dis, 2010, 13(4): 288-293.Malaviya AN, Sharma A, Agarwal D, et al. Low-dose and high-dose
methotrexate are two different drugs in practical terms[ J]. Int J Rheum
Dis, 2010, 13(4): 288-293.
83、Wakefield D, McCluskey P, Wildner G, et al. Inflammatory eye
disease: pre-treatment assessment of patients prior to commencing
immunosuppressive and biologic therapy: recommendations from an
expert committee[ J]. Autoimmun Rev, 2017, 16(3): 213-222.Wakefield D, McCluskey P, Wildner G, et al. Inflammatory eye
disease: pre-treatment assessment of patients prior to commencing
immunosuppressive and biologic therapy: recommendations from an
expert committee[ J]. Autoimmun Rev, 2017, 16(3): 213-222.
84、Hassan M, Karkhur S, Bae JH, et al. New therapies in development
for the management of non-infectious uveitis: a review[ J]. Clin Exp
Ophthalmol, 2019, 47(3): 396-417.Hassan M, Karkhur S, Bae JH, et al. New therapies in development
for the management of non-infectious uveitis: a review[ J]. Clin Exp
Ophthalmol, 2019, 47(3): 396-417.
